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essential for two reasons. Firstly, patients with positive neck nodes
have a higher risk of developing DM as have those with negative
neck nodes (Leemans et al, 1993; Mamelle et al, 1994). Secondly, a
heterogeneity between the tumour cell populations of the primary
tumour site and the neck nodes is possible. Therefore an analysis of
the distribution of markers in the cervical nodes is essential.
Consequently, the results are questionable at this point in time.
A case-control study in which only patients with negative neck
nodes are selected will define which immunohistochemical
markers are related to DM.
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Sir,
As explained in our paper, the aim of our work was to study if
histological or biological factors, determined on initial biopsy
before treatment, could provide new prognostic information. It is a
clinical question, because it can help the clinician to choose the
initial treatment of the patient. For example, in the group of
patients with a higher risk to develop distant metastases, the clini-
cian could choose to begin with a general treatment (neo-adjuvant
chemotherapy for example) before the loco-regional treatment.
For that reason we focused on histo-biological factors which can
be determined before treatment.
The idea of studying immunohistochemical markers on neck
nodes is interesting, but it is a different question: it can only be
determined after surgery.
Nevertheless, the suggestion of Drs Carinci and Carls is impor-
tant. We are currently performing new studies so as to better
understand our results. We have seen that the expression of
c-erb-B2 can be present in non-transformed mucosa and disappear
in adjacent transformed mucosa (discussion of our paper). It will
be interesting to see if, when expressed in tumour, it can also
disappear in involved lymph nodes.
Thank you for your interest in our work.
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